Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma

Stephen Maxted Ansell, Thomas Matthew Habermann, Paul J. Kurtin, Thomas Elmer Witzig, Michael G. Chen, Chin Y. Li, David J. Inwards, Joseph P. Colgan

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Purpose: The International Prognostic Factor Index has been shown to predict the outcome of patients with predominantly B-cell lymphomas classified using traditional classifications, including the Working Formulation, but its prognostic importance has not been tested in a cohort of patients with exclusively T-cell lymphomas. This study was conducted to evaluate the prognostic significance of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma (PTCL). Patients and Methods: Seventy-eight patients (48 men and 30 women) with PTCL seen at a single institution between 1985 and 1995 were included in the analysis. The morphology and immunocytochemistry of all the original biopsy specimens were reviewed by a single pathologist and classified using the Revised European- American Lymphoma (REAL) classification. The International Prognostic Factor Index, as well as clinical and biochemical parameters, were evaluated by univariate and multivariate analyses to determine their association with patient outcome. Results: The International Prognostic Factor Index strongly predicted survival when all patients were included in the analysis (P < .001). For patients ≤ 60 years, the age-adjusted International Index significantly predicted long-term survival (P = .0218). For patients older than 60 years, the age-adjusted International Index also significantly predicted survival (P = .002). Liver involvement (P = .006) and bone marrow involvement (P = .014) were also significant prognostic factors in the univariate analysis, but only the International Index remained significant in the multivariate analysis (P = .001). Conclusion: The International Prognostic Factor Index, which significantly predicts outcome in patients with aggressive/intermediate-grade B-cell lymphomas, has similar prognostic importance in patients with PTCL.

Original languageEnglish (US)
Pages (from-to)2296-2301
Number of pages6
JournalJournal of Clinical Oncology
Volume15
Issue number6
StatePublished - Jun 1997

Fingerprint

Peripheral T-Cell Lymphoma
B-Cell Lymphoma
Survival
Multivariate Analysis
T-Cell Lymphoma
Non-Hodgkin's Lymphoma
Lymphoma
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. / Ansell, Stephen Maxted; Habermann, Thomas Matthew; Kurtin, Paul J.; Witzig, Thomas Elmer; Chen, Michael G.; Li, Chin Y.; Inwards, David J.; Colgan, Joseph P.

In: Journal of Clinical Oncology, Vol. 15, No. 6, 06.1997, p. 2296-2301.

Research output: Contribution to journalArticle

@article{295ad8302e2a45bea500de6a926d6a6c,
title = "Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma",
abstract = "Purpose: The International Prognostic Factor Index has been shown to predict the outcome of patients with predominantly B-cell lymphomas classified using traditional classifications, including the Working Formulation, but its prognostic importance has not been tested in a cohort of patients with exclusively T-cell lymphomas. This study was conducted to evaluate the prognostic significance of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma (PTCL). Patients and Methods: Seventy-eight patients (48 men and 30 women) with PTCL seen at a single institution between 1985 and 1995 were included in the analysis. The morphology and immunocytochemistry of all the original biopsy specimens were reviewed by a single pathologist and classified using the Revised European- American Lymphoma (REAL) classification. The International Prognostic Factor Index, as well as clinical and biochemical parameters, were evaluated by univariate and multivariate analyses to determine their association with patient outcome. Results: The International Prognostic Factor Index strongly predicted survival when all patients were included in the analysis (P < .001). For patients ≤ 60 years, the age-adjusted International Index significantly predicted long-term survival (P = .0218). For patients older than 60 years, the age-adjusted International Index also significantly predicted survival (P = .002). Liver involvement (P = .006) and bone marrow involvement (P = .014) were also significant prognostic factors in the univariate analysis, but only the International Index remained significant in the multivariate analysis (P = .001). Conclusion: The International Prognostic Factor Index, which significantly predicts outcome in patients with aggressive/intermediate-grade B-cell lymphomas, has similar prognostic importance in patients with PTCL.",
author = "Ansell, {Stephen Maxted} and Habermann, {Thomas Matthew} and Kurtin, {Paul J.} and Witzig, {Thomas Elmer} and Chen, {Michael G.} and Li, {Chin Y.} and Inwards, {David J.} and Colgan, {Joseph P.}",
year = "1997",
month = "6",
language = "English (US)",
volume = "15",
pages = "2296--2301",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma

AU - Ansell, Stephen Maxted

AU - Habermann, Thomas Matthew

AU - Kurtin, Paul J.

AU - Witzig, Thomas Elmer

AU - Chen, Michael G.

AU - Li, Chin Y.

AU - Inwards, David J.

AU - Colgan, Joseph P.

PY - 1997/6

Y1 - 1997/6

N2 - Purpose: The International Prognostic Factor Index has been shown to predict the outcome of patients with predominantly B-cell lymphomas classified using traditional classifications, including the Working Formulation, but its prognostic importance has not been tested in a cohort of patients with exclusively T-cell lymphomas. This study was conducted to evaluate the prognostic significance of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma (PTCL). Patients and Methods: Seventy-eight patients (48 men and 30 women) with PTCL seen at a single institution between 1985 and 1995 were included in the analysis. The morphology and immunocytochemistry of all the original biopsy specimens were reviewed by a single pathologist and classified using the Revised European- American Lymphoma (REAL) classification. The International Prognostic Factor Index, as well as clinical and biochemical parameters, were evaluated by univariate and multivariate analyses to determine their association with patient outcome. Results: The International Prognostic Factor Index strongly predicted survival when all patients were included in the analysis (P < .001). For patients ≤ 60 years, the age-adjusted International Index significantly predicted long-term survival (P = .0218). For patients older than 60 years, the age-adjusted International Index also significantly predicted survival (P = .002). Liver involvement (P = .006) and bone marrow involvement (P = .014) were also significant prognostic factors in the univariate analysis, but only the International Index remained significant in the multivariate analysis (P = .001). Conclusion: The International Prognostic Factor Index, which significantly predicts outcome in patients with aggressive/intermediate-grade B-cell lymphomas, has similar prognostic importance in patients with PTCL.

AB - Purpose: The International Prognostic Factor Index has been shown to predict the outcome of patients with predominantly B-cell lymphomas classified using traditional classifications, including the Working Formulation, but its prognostic importance has not been tested in a cohort of patients with exclusively T-cell lymphomas. This study was conducted to evaluate the prognostic significance of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma (PTCL). Patients and Methods: Seventy-eight patients (48 men and 30 women) with PTCL seen at a single institution between 1985 and 1995 were included in the analysis. The morphology and immunocytochemistry of all the original biopsy specimens were reviewed by a single pathologist and classified using the Revised European- American Lymphoma (REAL) classification. The International Prognostic Factor Index, as well as clinical and biochemical parameters, were evaluated by univariate and multivariate analyses to determine their association with patient outcome. Results: The International Prognostic Factor Index strongly predicted survival when all patients were included in the analysis (P < .001). For patients ≤ 60 years, the age-adjusted International Index significantly predicted long-term survival (P = .0218). For patients older than 60 years, the age-adjusted International Index also significantly predicted survival (P = .002). Liver involvement (P = .006) and bone marrow involvement (P = .014) were also significant prognostic factors in the univariate analysis, but only the International Index remained significant in the multivariate analysis (P = .001). Conclusion: The International Prognostic Factor Index, which significantly predicts outcome in patients with aggressive/intermediate-grade B-cell lymphomas, has similar prognostic importance in patients with PTCL.

UR - http://www.scopus.com/inward/record.url?scp=0030902378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030902378&partnerID=8YFLogxK

M3 - Article

C2 - 9196143

AN - SCOPUS:0030902378

VL - 15

SP - 2296

EP - 2301

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -